Products

Solutions Designed with Better Care in Mind

At Teikoku Pharma USA, we are developing products that help address true unmet needs in the areas of CNS, pain management, and dermatology  – with a proven track record in effective non-opioid pain management products.

Lidoderm®
Lidocaine 5% Patch (US)

Lidoderm was the first prescription hydrogel patch approved in the United States for post-herpetic neuralgia (PHN). This pioneering transdermal technology is a pain management product that provides pain relief after a shingles infection for up to three days.

LEARN MORE
Versatis®
Lidocaine 5% Patch (EU)

A topical 5% medicated lidocaine plaster prescribed for the management of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN), also known as after-shingles pain.

LEARN MORE

RESEARCH & DEVELOPMENT

Uncovering What’s Possible

As a global pharmaceutical company with deep expertise in dosage form development plus comprehensive manufacturing capabilities, we create both the formulations and the delivery mechanisms that bring first and best in class therapies to life.

VIEW PIPELINE

FEATURED NEWS

NEWS

Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm® in China on May 8, 2024 

Read
NEWS

Teikoku Pharma USA announces positive topline results from Phase 2 clinical trial of TPU-006, non-opioid pain management patch in Abdominoplasty Surgery.

Read
NEWS

President and CEO Misako Fujioka Interviewed in Newsweek International

Read
NEWS

Teikoku Pharma granted FDA Fast Track Designation for TPU-006, a Novel 4-day Dexmedetomidine Transdermal System for Post Operative Pain Management

Read
NEWS

Change in The Board of Directors

Read
NEWS

Notice of Launch of ALLYDONE® Patches 27.5 mg / ALLYDONE® Patches 55 mg in Japan as Japan’s First Donepezil Transdermal Therapeutic System

Read
NEWS

Manufacturing and Marketing Approval Received in Japan for ALLYDONE® Patches for Treatment of Dementia Due to Alzheimer’s Disease as Japan’s First Donepezil Transdermal Therapeutic System

Read
NEWS

Execution of a license agreement on an exclusive marketing right in Japan of the first donepezil transdermal therapeutic system in Japan

Read
NEWS

TEIKOKU SEIYAKU was selected as A Global Niche Top Company by METI in FY2020.

Read
NEWS

Change in The Board of Directors

Read
VIEW ALL

CONTACT US

Contact us for distribution or licensing opportunities, or to learn more about our growing portfolio of life-changing drug therapies.

"*" indicates required fields

Policy*